Barrett Asset Management LLC raised its stake in shares of iShares NASDAQ Biotechnology Index (NASDAQ:IBB) by 200.0% in the 4th quarter, according to its most recent disclosure with the SEC. The firm owned 1,680 shares of the financial services provider’s stock after purchasing an additional 1,120 shares during the period. Barrett Asset Management LLC’s holdings in iShares NASDAQ Biotechnology Index were worth $179,000 as of its most recent SEC filing.

A number of other large investors also recently added to or reduced their stakes in IBB. Oppenheimer & Co. Inc. boosted its stake in shares of iShares NASDAQ Biotechnology Index by 182.0% in the fourth quarter. Oppenheimer & Co. Inc. now owns 45,699 shares of the financial services provider’s stock worth $4,879,000 after acquiring an additional 29,491 shares during the period. Family Firm Inc. boosted its stake in shares of iShares NASDAQ Biotechnology Index by 220.6% in the fourth quarter. Family Firm Inc. now owns 8,025 shares of the financial services provider’s stock worth $857,000 after acquiring an additional 5,522 shares during the period. Parkside Investments LLC boosted its stake in shares of iShares NASDAQ Biotechnology Index by 216.2% in the fourth quarter. Parkside Investments LLC now owns 51,487 shares of the financial services provider’s stock worth $5,497,000 after acquiring an additional 35,205 shares during the period. Glassman Wealth Services boosted its stake in shares of iShares NASDAQ Biotechnology Index by 199.8% in the fourth quarter. Glassman Wealth Services now owns 3,598 shares of the financial services provider’s stock worth $384,000 after acquiring an additional 2,398 shares during the period. Finally, MPI Investment Management Inc. bought a new position in shares of iShares NASDAQ Biotechnology Index in the fourth quarter worth about $2,002,000. 25.01% of the stock is owned by institutional investors and hedge funds.

iShares NASDAQ Biotechnology Index (NASDAQ:IBB) opened at $105.67 on Friday. The firm has a market capitalization of $9,400.00, a PE ratio of 3.49 and a beta of 1.37. iShares NASDAQ Biotechnology Index has a one year low of $93.67 and a one year high of $119.30.

TRADEMARK VIOLATION WARNING: “Barrett Asset Management LLC Buys 1,120 Shares of iShares NASDAQ Biotechnology Index (IBB)” was originally reported by TheOlympiaReport and is the property of of TheOlympiaReport. If you are reading this news story on another site, it was illegally stolen and republished in violation of United States and international trademark and copyright legislation. The original version of this news story can be read at https://theolympiareport.com/2018/02/11/barrett-asset-management-llc-buys-1120-shares-of-ishares-nasdaq-biotechnology-index-ibb.html.

About iShares NASDAQ Biotechnology Index

iShares Nasdaq Biotechnology ETF (the Fund), formerly iShares Nasdaq Biotechnology Index Fund, is an exchange-traded fund (ETF). The Fund seeks investment results that correspond generally to the price and yield performance of the NASDAQ Biotechnology Index (the Index). The Index contains securities of NASDAQ listed companies that are classified according to the Industry Classification Benchmark as either biotechnology or pharmaceuticals, which also meet other eligibility criteria determined by NASDAQ.

Institutional Ownership by Quarter for iShares NASDAQ Biotechnology Index (NASDAQ:IBB)

Receive News & Ratings for iShares NASDAQ Biotechnology Index Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for iShares NASDAQ Biotechnology Index and related companies with MarketBeat.com's FREE daily email newsletter.